Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23629)	7/28/1998 1:02:00 AM
From: Robert L. Ray	Read Replies (3) \| Respond to of 32384

>>>I haven't heard the news<<< I heard the negative report on Rezulin on the evening news. ABC I think but I'm not sure. They mentioned the liver toxicity problems, and the deaths, and 3 people had subsequently undergone liver transplants. Also mentioned was that since it's approval the drug's labeling had been changed 3 different times, and that now very strict testing was being done for people taking Rezulin. A liver test a month for the first 8 months. Then??? I really can't remember exactly.... something like a test every 2-3 months for the next year or two??.... and then "periodic" testing thereafter. It was mentioned that Rezulin had gotten fast track review and some guy speculated that the review wasn't extensive enough. It was further postulated that the rigorious testing now required would limit the market potential of Rezulin; not only because of the inconvienance but because of the added expense the testing entails.